Sugammadex for Reversal of Neuromuscular Blockade in Neonates and Infants Less than 2 Years Old: Results from a Phase IV Randomized Clinical Trial
In children less than 2 yr old, 2 mg/kg sugammadex reversed moderate NMB faster than neostigmine, and 4 mg/kg sugammadex rapidly reversed deep NMB. Sugammadex doses of 2 and 4 mg/kg were well tolerated.
Authors
- Yuki Mukai (ORCID: https://orcid.org/0000-0002-0000-1199)
- Maria Matuszczak (ORCID: https://orcid.org/0000-0002-9261-6755)
- Vera Saldien (ORCID: https://orcid.org/0000-0002-5151-8999)
- Heather Leibensperger
- Amy Locco
- Alison Gee
- W. Joseph Herring (ORCID: https://orcid.org/0000-0001-9133-031X)
- Marcel Speek
- Edith Mensah‐Osman
- Rebecca E. Wrishko (ORCID: https://orcid.org/0000-0003-2242-8326)
- Aobo Wang (ORCID: https://orcid.org/0000-0003-1377-1106)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Antwerp University Hospital (BE)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Anesthesiology
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1097/aln.0000000000005535
- Citations
- 7
- Primary Topic
- Anesthesia and Neurotoxicity Research
- Type
- article
- Field-Weighted Citation Impact
- 9.23